Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ipca Laboratories Ltd. Capital/Financing Update 2021

Oct 29, 2021

61700_rns_2021-10-29_4bef18cb-3d86-41f2-bc99-9ab9dc3a9c02.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

THRU ONLINE FILING

October 29, 2021

BSE Ltd. Phiroze Jeejeebhoy Towers Dalai Street Mumbai 400 023 Scrip Code - 524494

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra -(East). Mumbai-400051. Scrip Code : IPCALAB

Sub: Re-affirmation of CRISIL rating for Company's Rs. 200 Crore (Enhanced from Rs. 50 Crore) commercial paper

This is to inform you that CRISIL has re-affirmed its rating for the Company's commercial paper programme:

Rs. 200 Crore (Enhanced from Rs. 50
Crore) Commercial Paper
CRISIL A1+ (Reaffirmed)
---------------------------------------------------------------- ------------------------- --

This is for your information and record.

'Thanking you

Yours faithfully For Ipca Laboratories Limited

Harish P. Kamath Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.

www.ipca.com

'

125,Kandivli Industrial Estate,CIS No.328,Kandivli (West),Mumbai400067 (Maharashtra), India | T:+91 22 62105000 F:+91 22 62105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: [email protected] CIN: L24239MH1949PLC007837